Voyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen Sells 7,666 Shares

Key Points

• Nathan Jorgensen, CFO of Voyager Therapeutics, sold 7,666 shares at an average price of $4.78, totaling approximately $36,643, which reduced his holdings by 5.83%.
• Voyager Therapeutics reported a quarterly loss of ($0.57) EPS, falling short of the consensus estimate of ($0.48), with revenues of $5.20 million compared to the expected $9.50 million.
• Analysts have mixed ratings on the stock, with one "Strong Buy", seven "Buy", one "Sell", and a consensus price target of $13.25, despite a recent downgrade from Wedbush to $8.00.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CFO Nathan Jorgensen sold 7,666 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares of the company's stock, valued at $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Voyager Therapeutics Price Performance

Shares of VYGR traded down $0.22 during midday trading on Tuesday, hitting $4.73. The stock had a trading volume of 981,037 shares, compared to its average volume of 565,956. The stock's 50 day moving average is $3.84 and its 200 day moving average is $3.46. The firm has a market cap of $262.37 million, a PE ratio of -2.56 and a beta of 0.95. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. As a group, equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on VYGR shares. Weiss Ratings reiterated a "sell (d)" rating on shares of Voyager Therapeutics in a report on Saturday, September 27th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, September 15th. Finally, Wedbush reduced their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.25.

Institutional Trading of Voyager Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VYGR. CWM LLC grew its stake in shares of Voyager Therapeutics by 856.3% during the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the period. Bank of Montreal Can acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at $36,000. R Squared Ltd purchased a new stake in Voyager Therapeutics in the 2nd quarter worth $48,000. Los Angeles Capital Management LLC acquired a new position in Voyager Therapeutics during the second quarter worth $50,000. Finally, Privium Fund Management B.V. purchased a new position in Voyager Therapeutics during the first quarter valued at $73,000. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.